Evidence map›Paper›PMID 30250297›Full record

ArticleOncogene2019

Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.

Weiwei Yu, Jie Ding, Maio He, Yuan Chen, Ronghao Wang, Zhenwei Han, Emily Z Xing, Cuntai Zhang, Shuyuan Yeh

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 118 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Weiwei Yu *General Department of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Jie Ding *George Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Maio HeGeorge Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Yuan ChenGeneral Department of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Ronghao WangGeorge Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Zhenwei HanGeorge Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Emily Z XingGeorge Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Cuntai ZhangGeneral Department of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. ctzhang0425@163.com.
Shuyuan YehGeorge Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA. shuyuan_yeh@URMC.Rochester.edu.
University of Rochester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While estrogen receptor β (ERβ) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alteration of the vasculogenic mimicry (VM) formation to influence the NSCLC cell invasion remains unclear. Here, we analyzed immunohistochemistry data from NSCLC tissues and found that ERβ-positive NSCLC female patients had worse survival outcomes than those of ERβ-negative NSCLC female patients. In vitro studies using multiple NSCLC cell lines also revealed that ERβ could increase the VM formation and cell invasion. Molecular mechanism dissection suggested that ERβ could increase the lncRNA-MALAT1 (MALAT1) expression via directly binding to the estrogen response elements (EREs) located on the promoter of MALAT1, which could then lead to (i) suppressing the miR145-5p and (ii) increasing the NEDD9 protein expression as miR145-5p can directly target the 3'-UTR of NEDD9-mRNA. A preclinical study using the in vivo mouse model further confirmed the in vitro cell lines data. Together, results from the above studies demonstrated that ERβ can promote NSCLC VM formation and cell invasion via altering the ERβ/MALAT1/miR145-5p/NEDD9 signaling. Targeting this newly identified signaling pathway with small molecules may help the development of novel therapies to better suppress the NSCLC metastasis.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCell MovementCell ProliferationEstrogen Receptor betaGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceMicroRNAsNeoplasm InvasivenessNeovascularization, PathologicPhosphoproteinsRNA, Long NoncodingSignal TransductionAdaptor Proteins, Signal TransducingESR2 protein, humanEstrogen Receptor betaMALAT1 long non-coding RNA, humanMicroRNAsMIRN145 microRNA, humanNEDD9 protein, humanPhosphoproteinsRNA, Long Noncoding

Identifiers

PMID30250297
OpenAlexW2892712216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.